News
Resources
Blog
Sites
Gabby Migliara is a senior manager of public affairs at PhRMA focusing on the cost and value of medicines. She previously worked with the U.S. Census Bureau on marketing and communications for the 2020 Census campaign. Outside the office, Gabby enjoys trying new restaurants, hanging with her cat and exploring DC neighborhoods.
Recent Posts
CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease
By Gabby Migliara | September 1, 2022
There’s been a lot of discussion this year about the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) for new Alzheimer’s treatments finalized earlier this year in...
Read More
Celebrating Medicare’s 57th anniversary
By Gabby Migliara | August 2, 2022
In case you missed it, Saturday, July 30, marked the anniversary of Medicare. For 57 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans...
Read More
New research shows competition driven by biosimilars helps control costs in Part B
By Gabby Migliara | July 19, 2022
Discussions about spending in Medicare Part B, including a recent report from the Medicare Payment Advisory Commission, or MedPAC, too often overlook how competition between medicines drives down the...
Read More
Counterfeit pills on social media are a stark reminder of how importation schemes could further threaten patient lives
By Gabby Migliara | July 6, 2022
Last month, as part of efforts to advance legislation reauthorizing the critical U.S. Food and Drug Administration (FDA) user fee agreements, the Senate HELP Committee included a dangerous proposal...
Read More
Why drug importation is bad for Americans
By Gabby Migliara | May 12, 2022
Drug importation schemes are dangerous and have significant negative consequences for both individuals and our health care system. Importation refers to when governments or individuals circumvent the...
Read More
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
By Gabby Migliara | April 28, 2022
Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. We’ve made...
Read More
Part D 101: Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
By Gabby Migliara | April 27, 2022
In yesterday’s post, we learned how Medicare Part D works for seniors and people with disabilities. Unfortunately, Part D beneficiaries are increasingly facing higher out-of-pocket costs for the...
Read More
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage
By Gabby Migliara | April 26, 2022
Medicare Part D provides prescription drug coverage for our nation’s seniors and Americans with disabilities. These beneficiaries can opt to enroll in Part D and pick from a variety of plans offered....
Read More
New analysis confirms hospitals markup prices for oncology therapies
By Gabby Migliara | April 21, 2022
A recent study from The Journal of the American Medical Association (JAMA) examined 61 hospitals using data made public under new requirements from a recent price transparency regulation. The...
Read More
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
By Gabby Migliara | March 11, 2022
The U.S. Department of Veterans Affairs (VA) primarily provides medical coverage for veterans who have experienced service-related disabilities. Its unique system was developed to meet the targeted...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
